Program
aflibercept
Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.
Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 251 open or running | phase 4since Nov 2, 2012 | May 13, 2002 | none ahead |
| Bayerits history only | 230 open or running | phase 4since Apr 10, 2014 | Mar 12, 2008 | none ahead |
| Sanofi | 200 open or running | phase 3since May 16, 2006 | Jan 30, 2006 | none ahead |
| Novartisits history only | 40 open or running | phase 4since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Amgenits history only | 31 open or running | phase 3since Feb 13, 2020 | Feb 13, 2020 | Jul 31, 2027phase 3 · NCT07614776 |
| Sam Chun Dang Pharm.its history only | 20 open or running | phase 3since Jul 17, 2020 | Jul 17, 2020 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Mar 16, 2022 | Mar 16, 2022 | Jun 2031phase 2 · NCT05296447 |
| AO GENERIUMits history only | 11 open or running | phase 3since Sep 18, 2026 | Sep 18, 2026 | May 2028phase 3 · NCT07844148 |
| bioeq-gmbhits history only | 10 open or running | phase 3since Aug 11, 2020 | Aug 11, 2020 | none ahead |
| cinnagenits history only | 10 open or running | phase 3since Sep 18, 2022 | Sep 18, 2022 | none ahead |
| Exegenesis Bioits history only | 11 open or running | phase 1since Jan 30, 2025 | Jan 30, 2025 | Feb 2029phase 1 · NCT06817343 |
| formycon-agits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 19, 2022 | Apr 19, 2022 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | none ahead |
| the-emmes-company-llcits history only | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
Also a collaborator on its studies: REGENXBIO and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Jan 30, 2006.
- Sep 19, 2007Phase 3 study in CarcinomaNCT00532155 · 913 enrolled · United States, Argentina, Australia and more
- Oct 16, 2007Phase 1 study in NeoplasmsNCT00545246 · 12 enrolled · Japan
- Nov 20, 2007Phase 3 study in Colorectal NeoplasmsNCT00561470 · 1,226 enrolled · United States, Argentina, Australia and more
- Dec 14, 2007Phase 3 study in Pancreatic NeoplasmsNCT00574275 · 546 enrolled · United States, Argentina, Austria and more
- Mar 21, 2008Phase 1 study in Lymphoma, Non-HodgkinNCT00644124 · 25 enrolled · France
- Feb 24, 2009Phase 2 study in Colorectal NeoplasmsNCT00851084 · 268 enrolled · Australia, Germany, Italy and more
- Apr 3, 2009Phase 1 study in NeoplasmsNCT00876044 · 88 enrolled · United States, Belgium, Denmark and more
- Jun 15, 2009Phase 1 study in Colorectal NeoplasmsNCT00921661 · 16 enrolled · Japan
- Jun 21, 2010Phase 1 study in NeoplasmsNCT01148615 · 20 enrolled · China
- Apr 3, 2012Phase 3 study in Colorectal Cancer MetastaticNCT01571284 · 781 enrolled · United States, Belgium, Brazil and more
- Jul 13, 2012Phase 3 study in Colorectal Cancer MetastaticNCT01670721 · 175 enrolled · France
- Aug 7, 2012Phase 3 study in Colorectal Cancer MetastaticNCT01661270 · 332 enrolled · China, Hong Kong, Japan and more
- Jun 18, 2013Phase 2 study in Colorectal Cancer MetastaticNCT01882868 · 62 enrolled · Japan
- Sep 13, 2013Phase 2 study in Colorectal Cancer MetastaticNCT01955629 · 4 enrolled · Italy
- Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
TargetBeta
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule
Studies
All 20 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01955629Colorectal Cancer Metastatic · Italy | 2 | Terminated | Mar 2015 | 4 |
| NCT01882868Colorectal Cancer Metastatic · Japan | 2 | Completed | Aug 2015 | 62 |
| NCT01661270Colorectal Cancer Metastatic · China, Hong Kong, Japan and more | 3 | Completed | Oct 2014 | 332 |
| NCT01670721Colorectal Cancer Metastatic · France | 3 | Completed | Jun 2015 | 175 |
| NCT01571284Colorectal Cancer Metastatic · United States, Belgium, Brazil and more | 3 | Completed | Jan 31, 2017 | 781 |
| NCT01148615Neoplasms · China | 1 | Completed | Sep 2011 | 20 |
| NCT00921661Colorectal Neoplasms · Japan | 1 | Completed | Jun 2012 | 16 |
| NCT00876044Neoplasms · United States, Belgium, Denmark and more | 1 | Completed | Feb 2010 | 88 |
| NCT00851084Colorectal Neoplasms · Australia, Germany, Italy and more | 2 | Completed | Apr 2011 | 268 |
| NCT00644124Lymphoma, Non-Hodgkin · France | 1 | Completed | Oct 2011 | 25 |
| NCT00574275Pancreatic Neoplasms · United States, Argentina, Austria and more | 3 | Terminated | Oct 2009 | 546 |
| NCT00561470Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Feb 2011 | 1,226 |
| NCT00545246Neoplasms · Japan | 1 | Completed | Jul 2012 | 12 |
| NCT00532155Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Jan 2011 | 913 |
| NCT00519285Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Apr 2012 | 1,224 |
| NCT00479076Neoplasms · Japan | 1 | Completed | Jan 2011 | 22 |
| NCT00396591Ovarian Neoplasms · United States, Italy, Sweden | 2 | Completed | Nov 2008 | 16 |
| NCT00327444Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Oct 2009 | 58 |
| NCT00327171Neoplasms · United States, Australia, Canada and more | 2 | Completed | Apr 2008 | 218 |
| NCT00284141Lung Diseases · United States, Canada, France | 2 | Completed | Jul 2008 | 98 |
How it is read
Names in the registry
- “Aflibercept”, 9 entries
- “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept”, 7 entries
- “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries
Codes read as this program: BAY865321, SCD411.
Conditions, from the studies’ own filings
- Macular Degeneration, 28 studies
- Macular Edema, 15 studies
- Colorectal Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Retinal Vein Occlusion, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.